newsfilter
← Latest News
Business Wire·

Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products

  • Zai Lab Limited announced that five of its commercial medicines in China were included in the 2026 National Reimbursement Drug List (NRDL).
  • The 2026 NRDL update features two first-time listings: VYVGART Hytrulo for adult gMG & KarXT for adult schizophrenia.
  • The update also includes three renewals for NUZYRA (community-acquired bacterial pneumonia & skin infections), QINLOCK (advanced GIST), & AUGTYRO (ROS1-positive NSCLC & NTRK fusion solid tumors).
  • VYVGART Hytrulo provides subcutaneous administration convenience for gMG patients.
  • KarXT utilizes a novel mechanism of action for schizophrenia treatment.
  • The 2026 NRDL will become effective on January 1, 2027.
  • Specific dosage specifications for KarXT were defined for the reimbursement scope.
  • Reimbursement for AUGTYRO in NTRK fusion-positive solid tumors is restricted to patients with locally advanced/metastatic disease, severe surgical complications, or failed prior treatments.